Drug · DIN 02238389
CAELYX
SINGLE-USE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 4, 2022; first marketed August 19, 1998.
- Drug Identification Number (DIN)
- 02238389
- Company (DIN owner)
- Baxter CorporationMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Suspension
- Route
- Intravenous
- Therapeutic class (ATC)
- Doxorubicin L01DB01
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DOXORUBICIN HYDROCHLORIDE | 2 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 4, 2022: NOC 27717New Drug Submission (NDS) · Administrative: Change in Product Ownership
- January 4, 2011: NOC 11974New Drug Submission (NDS) · Manufacturer name change
- July 20, 1998: NOC 2825New Drug Submission (NDS)